Last updated: March 2, 2026
What excipients are used in the formulation of ALL DAY RELIEF?
ALL DAY RELIEF, a marketed over-the-counter (OTC) analgesic, likely employs a formulation optimized for stability, bioavailability, and patient compliance. Common excipients in such formulations include:
- Binders: microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC)
- Fillers/Diluents: lactose monohydrate, microcrystalline cellulose
- Disintegrants: croscarmellose sodium, sodium starch glycolate
- Lubricants: magnesium stearate, stearic acid
- Coatings and Glidants: silicon dioxide, coating polymers for stability and controlled release
Exact excipients depend on the dosage form (tablet, capsule, liquid). For sustained-release formulations, polymers like ethylcellulose or polyvinyl acetate might be used to control drug release kinetics.
How does excipient choice impact the drug’s performance and shelf life?
Excipient choices influence:
- Stability: Antioxidants or coating agents protect APIs from degradation.
- Bioavailability: Disintegrants facilitate rapid dissolution; solubilizers enhance absorption.
- Manufacturability: Flowability and compressibility affect process efficiency.
- Patient compliance: Flavoring agents or sweeteners improve palatability for liquids or chewables.
Selecting non-reactive, inert excipients minimizes potential for adverse reactions and extends shelf life. For ALL DAY RELIEF, excipients must support stability for extended shelf life, potentially up to two years.
What are the key regulatory considerations for excipient selection?
Regulatory agencies like the FDA and EMA mandate:
- GRAS status: excipients must be Generally Recognized as Safe.
- Documentation: qualificatory data on source, purity, and intended use.
- Consistency: batch-to-batch uniformity in excipient composition.
- Restriction: use of certain excipients in specific age groups (e.g., children).
Manufacturers typically refer to the FDA’s Inactive Ingredient Database (IID) and EMA guidelines to ensure compliance.
What are the commercial opportunities linked to excipient innovation?
Opportunities include:
- Targeted Release: Developing excipient matrices that provide controlled or delayed release, extending product differentiation.
- Palatability: Introducing novel flavoring or sweetening excipients that enhance patient adherence, especially for pediatric or geriatric populations.
- Enhanced Stability: Using antioxidant or superdisintegrant excipients to lengthen shelf life and improve robustness.
- Reduced Side Effects: Utilizing inert, hypoallergenic excipients to broaden market access, including sensitive populations.
- Cost Optimization: Sourcing excipients from cost-effective suppliers without compromising quality, improving margins or lowering end-user price.
Partnerships with excipient suppliers focusing on customized formulations represent a strategic pathway for differentiation.
How can companies leverage excipient strategies to expand market presence?
Companies should:
- Invest in R&D for innovative excipient formulations that enable controlled-release or taste-masking.
- Gain intellectual property rights through patents covering specific excipient-marked drug combinations or delivery methods.
- Implement quality-by-design (QbD) principles to optimize excipient composition for stability and performance.
- Engage in know-how sharing and collaboration with excipient manufacturers to develop proprietary excipient blends.
- Focus on regulatory submission excellence, including detailed excipient profiles and stability data, to facilitate approvals.
Summary of key points
| Aspect |
Details |
| Common excipients |
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, lactose |
| Impact on performance |
Influence stability, bioavailability, manufacturability, palatability |
| Regulatory considerations |
GRAS status, purity, batch consistency, age restrictions |
| Commercial opportunities |
Controlled release, taste-masking, stability, hypoallergenic excipients |
| Market expansion tactics |
Innovation, IP protection, QbD, supplier collaboration |
Key Takeaways
- Excipient selection affects drug stability, release profile, patient compliance, and regulatory approval.
- Innovation in excipients provides avenues for formulation differentiation and market expansion.
- Regulatory compliance demands meticulous documentation and quality control on excipient sourcing.
- Cost-effective and robust excipient strategies can improve margins and competitive positioning.
- Collaboration with specialized excipient suppliers enhances formulation capabilities.
FAQs
1. Can new excipients be patented for ALL DAY RELIEF formulations?
Yes. Novel combinations or applications of existing excipients can be patentable if they provide unique formulation benefits.
2. How do excipients affect the shelf life of ALL DAY RELIEF?
They influence stability by protecting the API from degradation, controlling moisture, or preventing chemical interactions, thereby extending shelf life.
3. Are there specific excipients to avoid in formulations for sensitive populations?
Yes. Excipients like certain preservatives or artificial flavors may cause adverse reactions. In such cases, hypoallergenic and inert excipients are chosen.
4. How important is regulatory documentation for excipient use?
Critical. It ensures compliance and smooth approval processes; hence, detailed sourcing, purity, and stability data are necessary.
5. What trends are shaping excipient innovation for OTC drugs?
Use of biocompatible, sustainable, and functionality-enhancing excipients; emphasis on taste-masking; and development of controlled-release systems.
References
[1] U.S. Food and Drug Administration. (2021). Inactive Ingredient Database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database
[2] European Medicines Agency. (2022). Guidelines on excipients in the labeling and package leaflet of medicinal products for human use. EMA/CHMP.
[3] Park, K., & Kim, G. (2020). Excipient strategies for controlled release oral drug formulations. Journal of Pharmaceutical Sciences, 109(11), 3755-3762.
